Moderna Looks To mRNA To Crack Challenge Of HIV Vaccine

mRNA Will Speed Development Time

The Bill Gates Foundation-backed partnership with IAVI could bring a HIV vaccine a step closer, but generating the right antibody response has defeated many previous attempts.

Moderna believes its mRNA know-how, which has proven so successful against COVID-19, could also help finally crack the challenge of developing a HIV vaccine, and has just launched a Phase I study with academic partners.

While antiretroviral therapies are able to suppress HIV for a lifetime once individuals are infected, there remains a need for...

More from Business

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

More from Scrip

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.